Hypermagnesemia does not prevent intracranial hypertension and aggravates cerebral hyperperfusion in a rat model of acute hyperammonemia

Peter Nissen Bjerring, Martin Eefsen, Fin Stolze Larsen, William Bernal, Julia Wendon – 7 March 2011 – Intravenous infusion of magnesium sulfate prevents seizures in patients with eclampsia and brain edema after traumatic brain injury. Neuroprotection is achieved by controlling cerebral blood flow (CBF), intracranial pressure, neuronal glutamate release, and aquaporin‐4 (Aqp4) expression. These factors are also thought to be involved in the development of brain edema in acute liver failure.

Critical care issues in patients after liver transplantation

Raymund R. Razonable, James Y. Findlay, Aisling O'Riordan, S. Gordon Burroughs, R. Mark Ghobrial, Banwari Agarwal, Andrew Davenport, Michael Gropper – 7 March 2011 – The majority of patients who undergo liver transplantation (LT) spend some time in the intensive care unit during the postoperative period. For some, this is an expected part of the immediate posttransplant recovery period, whereas for others, the stay is more prolonged because of preexisting conditions, intraoperative events, or postoperative complications.

The stable repression of mesenchymal program is required for hepatocyte identity: A novel role for hepatocyte nuclear factor 4α

Laura Santangelo, Alessandra Marchetti, Carla Cicchini, Alice Conigliaro, Beatrice Conti, Carmine Mancone, Jessica A. Bonzo, Frank J. Gonzalez, Tonino Alonzi, Laura Amicone, Marco Tripodi – 7 March 2011 – The concept that cellular terminal differentiation is stably maintained once development is complete has been questioned by numerous observations showing that differentiated epithelium may undergo an epithelial‐to‐mesenchymal transition (EMT) program.

High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients

Keyur Patel, Joseph E. Lucas, J. Will Thompson, Laura G. Dubois, Hans L. Tillmann, Alexander J. Thompson, Diane Uzarski, Robert M. Califf, Martin A. Moseley, Geoffrey S. Ginsburg, John G. McHutchison, Jeanette J. McCarthy, for the MURDOCK Horizon 1 Study Team – 4 March 2011 – Chronic hepatitis C (CHC) infection is a leading cause of endstage liver disease. Current standard‐of‐care (SOC) interferon‐based therapy results in sustained virological response (SVR) in only one‐half of patients, and is associated with significant side effects.

Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

Silvia Sookoian, Carlos J. Pirola – 4 March 2011 – Our objective was to estimate the strength of the effect of the I148M (rs738409 C/G) patatin‐like phospholipase domain containing 3 (PNPLA3) variant on nonalcoholic fatty liver (NAFLD) and disease severity across different populations. We performed a systematic review by a meta‐analysis; literature searches identified 16 studies.

Interleukin‐32: A new proinflammatory cytokine involved in hepatitis C virus‐related liver inflammation and fibrosis

Alexander R. Moschen, Teresa Fritz, Andrew D. Clouston, Ilka Rebhan, Oliver Bauhofer, Helen D. Barrie, Elizabeth E. Powell, Soo‐Hyun Kim, Charles A. Dinarello, Ralf Bartenschlager, Julie R. Jonsson, Herbert Tilg – 4 March 2011 – Interleukin 32 (IL‐32) is a recently described proinflammatory cytokine that activates p38 mitogen‐activated protein kinase (MAPK) and nuclear factor kappa B (NF‐κB), thereby inducing proinflammatory cytokines such as IL‐1β and tumor necrosis factor alpha (TNF‐α). We investigated the role of IL‐32 in patients with chronic hepatitis C virus (HCV) infection.

Subscribe to